Bridgeway Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Bridgeway Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$154K	Hold	25,000	–	–	﹤0.01%	1073
2025 Q4	$180K	Hold	25,000	–	–	﹤0.01%	1039
2025 Q3	$256K	Buy	+25,000	New	+$281K	0.01%	966
2024 Q4	–	Sell	-10,193	Closed	-$164K	–	1282
2024 Q3	$164K	Hold	10,193	–	–	﹤0.01%	1102
2024 Q2	$275K	Hold	10,193	–	–	0.01%	982
2024 Q1	$199K	Sell	10,193 -5,000	-33%	-$106K	﹤0.01%	1111
2023 Q4	$314K	Hold	15,193	–	–	0.01%	1057
2023 Q3	$483K	Hold	15,193	–	–	0.01%	877
2023 Q2	$510K	Buy	15,193 +693	+5%	+$24.8K	0.01%	891
2023 Q1	$605K	Buy	+14,500	New	+$682K	0.02%	839
2022 Q4	–	Sell	-640	Closed	-$31K	–	1448
2022 Q3	$31K	Buy	+640	New	+$35.2K	﹤0.01%	1372
2020 Q2	–	Sell	-6,603	Closed	-$477K	–	1385
2020 Q1	$477K	Sell	6,603 -1,167	-15%	-$113K	0.01%	780
2019 Q4	$555K	Buy	7,770 +5,500	+242%	+$265K	0.01%	935
2019 Q3	$119K	Hold	2,270	–	–	﹤0.01%	1233
2019 Q2	$122K	Buy	+2,270	New	+$155K	﹤0.01%	1232
2018 Q4	–	Sell	-1,667	Closed	-$778K	–	1438
2018 Q3	$778K	Sell	1,667 -833	-33%	-$335K	0.01%	1001
2018 Q2	$994K	Hold	2,500	–	–	0.01%	878
2018 Q1	$764K	Buy	2,500 +1,667	+200%	+$475K	0.01%	936
2017 Q4	$245K	Hold	833	–	–	﹤0.01%	1247
2017 Q3	$456K	Hold	833	–	–	0.01%	1118
2017 Q2	$497K	Buy	+833	New	+$368K	0.01%	1093

Other funds holding RNAC

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgeway Capital Management's RNAC Position: Q1 2026 in Review

Bridgeway Capital Management held its Cartesian Therapeutics (RNAC) position steady in Q1 2026 at 25,000 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #1073.

Bridgeway Capital Management first reported a position in RNAC in Q2 2017 and has held it in 21 quarters since. The position peaked at $994K in Q2 2018. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

Bridgeway Capital Management held 25,000 shares of Cartesian Therapeutics worth $154K as of Q1 2026.
Bridgeway Capital Management left its Cartesian Therapeutics share count unchanged in Q1 2026.
Cartesian Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #1073 holding.
Bridgeway Capital Management first reported a position in Cartesian Therapeutics in Q2 2017 and has held it in 21 quarters since.
Bridgeway Capital Management's Cartesian Therapeutics position peaked at $994K in Q2 2018.
83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.